Lyell Immunopharma (LYEL) Current Assets (2020 - 2026)

Lyell Immunopharma has reported Current Assets for 7 years, with the latest figure at $267.3 million in Q1 2026.

• Quarterly Current Assets fell 13.54% year-over-year to $267.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.3 million (down 13.54% YoY) and the FY2025 annual result came in at $260.9 million, down 31.26% from the prior year.
• Current Assets rose to $267.3 million in Q1 2026 per LYEL's latest filing, from $260.9 million in the prior quarter.
• Over five years, Current Assets peaked at $666.8 million in Q2 2022 and troughed at $260.9 million in Q4 2025.
• A 5-year average of $487.5 million and a median of $534.2 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2025: Current Assets climbed 4.53% in 2022, then sank 43.54% in 2025.
• Over 5 years, Current Assets stood at $651.3 million in 2022, then declined by 14.83% to $554.7 million in 2023, then slumped by 31.57% to $379.6 million in 2024, then slumped by 31.26% to $260.9 million in 2025, then grew by 2.44% to $267.3 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $267.3 million, $260.9 million, and $328.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.